Home
Clinical Trials
ABSK-011+BSC vs. Placebo+BSC ...

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

Last Updated: 2026-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

141 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-13

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. Approximately 141 advanced or unresectable HCC patients with FGF19 overexpression who have received prior systemic therapy will be enrolled and randomized to experimental arm or control arm in a 2:1 ratio. Patients will receive assigned study treatment, every 28-day treatment cycle within 1 day of randomization until disease progression, intolerable toxicity, start of new anti-tumor therapy, death, patient refuse to continue treatment, loss to follow-up, or other reasons leading to treatment discontinuation. Immediate BICR review is required for patients with radiographic disease progression as assessed by the investigator. If disease progression is assessed by BICR, the investigator is allowed to unblind after disease progression according to the protocol-specified procedures. After unblinding, patients in the experimental arm, study drug should be discontinued. Patients in the control arm may be transferred to receive ABSK-011 plus BSC after assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FGF19 Overexpression Combination Unified Study in HCC-19

NCT06978933

HCC - Hepatocellular Carcinoma

RECRUITING PHASE2

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients

NCT05441475

Hepatocellular Carcinoma

UNKNOWN PHASE2

A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

NCT07239986

Hepatocellular Carcinoma (HCC)

NOT_YET_RECRUITING PHASE2

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

NCT05713994

Hepatocellular Carcinoma Non-resectable

RECRUITING

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

NCT00370513

Carcinoma, Hepatocellular

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma (HCC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental arm

ABSK-011 plus BSC

Group Type EXPERIMENTAL

ABSK-011+BSC

Intervention Type DRUG

ABSK-011 capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.

Control arm

Placebo plus BSC

Group Type PLACEBO_COMPARATOR

Placebo+BSC

Intervention Type DRUG

Placebo capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABSK-011+BSC

Intervention Type DRUG

Placebo+BSC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patients should be able and willing to comply with study visits and procedures as per protocol.
2. Patients (male or female) ≥ 18 years of age at the time of signing the informed consent form.
3. Patients with advanced or unresectable HCC confirmed histologically/cytologically or clinically according to the American Association for the Study of Liver Diseases (AASLD) criteria (for patients with cirrhosis).
4. Have received at least one prior PD- (L) 1 inhibitor approved as a single agent or in combination for the treatment of HCC and at least one mTKI approved for the treatment of HCC.
5. BCLC stage B(ineligible for local or radical therapy, or relapse or progression of disease after local therapy or radical therapy) or C.
6. Child-Pugh class A.
7. Positive for FGF19 overexpression.
8. At least 1 measurable lesion meeting RECIST v1.1 criteria.
9. ECOG performance status 0 or 1.
10. Life expectancy ≥ 3 months.
11. Adequate control of blood pressure (BP) at screening.
12. Adequate organ function and bone marrow function.
13. Non-surgically sterilized male or female patients of childbearing potential must agree to use reliable contraception for at least 2 weeks prior to randomization until 1 month after the last dose of study treatment.

Exclusion Criteria

1. Known allergies or hypersensitivity to any component of the investigational product (ABSK-011 or placebo).
2. Previous treatment with selective FGFR4 inhibitors.
3. Known fibrolamellar HCC, sarcomatous HCC, or mixed hepatocellular carcinoma-cholangiocarcinoma.
4. Previous anti-tumor therapy is ≤ 4 weeks from randomization.
5. Major surgery within 4 weeks prior to randomization; or any surgical wound infection, dehiscence, or incomplete healing within 2 weeks prior to randomization; Or major surgery is planned during study treatment.
6. History of second primary malignancies other than HCC within the first 5 years of screening.
7. Liver tumors as a percentage of whole liver ≥ 50% as judged by the investigator.
8. Toxicities caused by prior chemotherapy, radiotherapy, and other anti-tumor therapies (including immunotherapy) did not recover to ≤ Grade 1 CTCAE v5.0.
9. Imaging revealed HCC involving the main portal vein (Vp4), inferior vena cava, superior vena cava, superior mesenteric vein, or heart.
10. Impaired cardiac function or clinically important heart disease.
11. Patients coinfected with HBV and HCV.
12. Known acquired immunodeficiency syndrome (AIDS) -associated disease or tested positive for HIV 1/2 antibodies.
13. Active or documented gastrointestinal bleeding within 6 months prior to screening.
14. Patients with intractable/uncontrolled pleural or pericardial effusion requiring intervention within 2 weeks prior to randomization and clinically significant ascites.
15. Prior or current hepatic encephalopathy (any grade).
16. Presence of meningeal or central nervous system (CNS) metastases.
17. Previous organ transplant and anti-rejection drug therapy indicated.
18. The factors that significantly affect the absorption of oral drugs.
19. Receipt of P-gp transporter inhibitors or moderate, strong inhibitors or inducers of CYP3A4 within 2 weeks prior to randomization.
20. Any serious acute or chronic infection requiring systemic antibacterial, antifungal, or antiviral therapy within 2 weeks prior to randomization.
21. Patient who cannot be assessed by contrast-enhanced CT and/or MRI due to allergy to computed tomography (CT) and/or magnetic resonance imaging (MRI) contrast media or other contraindications.
22. Any other clinically significant comorbidities may affect the patient's health or safety, affect the signing of informed consent, affect protocol compliance, or interfere with the interpretation of the study results.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers